Profile data is unavailable for this security.
About the company
Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.
- Revenue in GBP (TTM)0.00
- Net income in GBP-5.86m
- Incorporated2008
- Employees61.00
- LocationScancell Holdings PLCUnit 202 Bellhouse BuildingSanders Road, Oxford Science ParkOXFORD OX4 4GDUnited KingdomGBR
- Phone+44 186 558 2066
- Fax+44 115 823 1863
- Websitehttps://www.scancell.co.uk/